Systematic pan-cancer analysis reveals XCR1 as a Prognostic and Immunological Biomarker

Abstract Background Chemokines and their receptors play an important role in immune monitoring and immune defense during the tumor growth and metastasis. However, their prognostic roles in pan-cancer were not elucidated. In this work, we screened all chemokine receptors in pan-cancer and discovered XCR1 as a reliable immunological and prognostic biomarker in pan-cancer using bioinformation. Methods The TCGA database served as the foundation for the primary research database analysis in this work. The screening of tumor patients' overall survival yielded XCR1, which had a favorable predictive connection. Further investigation into the connection between XCR1 expression and tumor development stage in tumor patients was done using the clinicopathological stage. The regulatory mechanism of XCR1 regulating tumor formation and as a prognostic molecule has also been discovered using enrichment analysis of XCR1-related genes. The spatial localization of XCR1 in tumor tissues was discovered by using single-cell databases. Result XCR1 was downregulated in tumors. Patients with reduced XCR1 showed worse prognoses and a concomitant decrease in immune cell infiltration (DCs and CD8 + T cells). According to gene enrichment study, XCR1 enhanced immune system performance by promoting T cell infiltration through the CXCL9-CXCR3 axis. In addition, XCR1 is mainly expressed on infiltrated DCs and some malignant cells in tumor tissues. Conclusion Our data revealed the important role of XCR1 in remodeling of the tumor microenvironment and predicting the survival prognosis, which could also be used as sensitive biomarker for tumor immunotherapy.